Safety and efficacy of radiotherapy with concurrent raltitrexed in older patients with esophageal cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029481

Enrollment

Unknown

Registered

2020-02-02

Start date

2020-02-10

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Experimental group:radiotherapy+ raltitrexed

control group:radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. aged>75 years; 2. pathologically proven esophageal carcinoma; 3. there are measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; 4. considered medically inoperable or refuse operation; 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 1 or less; 6. No previous radiotherapy or chemotherapy; 7. no other active malignant tumor; 8. adequate organ and marrow function; 9. All patients understand and provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe cachexia; 2. Concomitant radiotherapy contraindications such as esophageal tracheal fistula, esophageal vascular fistula, etc; 3. Severe infection or heart, lung, liver, kidney disease; 4. Severe mental illness; 5. Researchers believe patients are not suitable for enrollment.

Design outcomes

Primary

Measure	Time frame
Objective response rate;Safety;	—

Secondary

Measure	Time frame
Progression free survival;Overall survival;Quality of Life;	—

Countries

China

Contacts

Public ContactRong Feng

Lu'an people's Hospital

wazhl1996@163.com+86 13635649383

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026